Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Free Research Reports on AMD, IHS, MDCO and PERI Issued by the Bedford Report

AMD, PERI
Free Research Reports on AMD, IHS, MDCO and PERI Issued by the Bedford Report
http://media.marketwire.com/attachments/201211/53317_equitynewscircuit-logo-final.jpghttp://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=972361&ProfileId=051205&sourceType=1

NEW YORK, NY -- (Marketwire) -- 01/09/13 -- The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

Advanced Micro Devices, Inc. (NYSE: AMD) shares of the semiconductor company have declined over 50 percent in the past year. Standard & Poor's have recently downgraded the company's ratings as it expects further declines in AMD's revenues.

Find out more about Advanced Micro Devices including full access to the free equity report at: www.BedfordReport.com/AMD

IHS Inc. (NYSE: IHS) shares gained 5 percent on more than double the average daily volume Tuesday. The company's net income in the fiscal fourth quarter doubled when compared to the fourth quarter of 2011.

Find out more about IHS including full access to the free equity report at: www.BedfordReport.com/IHS

The Medicines Company (NASDAQ: MDCO) shares soared 12 percent on nearly 9-times the average daily volume Tuesday. The company reported positive results from a phase 3 trial of cangrelor, which is in development to prevent platelet activation and aggregation that leads to thrombosis in the acute care setting.

Find out more about The Medicines Company including full access to the free equity report at: www.BedfordReport.com/MDCO

Perion Network Ltd. (NASDAQ: PERI) shares hit a new all-time high of $12.47 on Tuesday as it traded nearly 4 million shares. The online services provider's full-year revenue of $61 million topped their previous forecasts of $55 million.

Find out more about Perion Network including full access to the free equity report at: www.BedfordReport.com/PERI

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.

A third party, Providence Media Strategies LLC has paid Equity News Circuit four hundred and fifty dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information:

Equity News Circuit
Email Contact



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today